2-氨基-4-甲基苯甲酰胺 | 39549-79-6

• 物质功能分类: 化学试剂 - 有机试剂 - 酰胺
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-4-甲基苯甲酰胺
• 中文别名: 2-氨基-4-甲基苯甲脒
• 英文名称: 2-amino-4-methylbenzamide
• CAS: 39549-79-6
• 化学式: C₈H₁₀N₂O
• 分子量: 150.18
• InChiKey: RUHKZVAPXHIWJH-UHFFFAOYSA-N

物化性质

• 熔点：
  147 °C
• 沸点：
  282.8±28.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H317,H319,H335
• 储存条件：
  室温下密封保存。

SDS

Name:	2-Amino-4-methylbenzamide 97% Material Safety Data Sheet
Synonym:
CAS:	39549-79-6

Section 1 - Chemical Product MSDS Name:2-Amino-4-methylbenzamide 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
39549-79-6	2-Amino-4-methylbenzamide	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 39549-79-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 142 - 144 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H10N2O
Molecular Weight: 150

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, bases, reducing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 39549-79-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Amino-4-methylbenzamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 39549-79-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 39549-79-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 39549-79-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-4-甲基苯甲酰胺 在 盐酸 、 sodium nitrite 作用下， 生成 7-methylbenzo[d][1,2,3]triazin-4(3H)-one
  参考文献：
  名称：

  Niementowski, Chemische Berichte, 1888, vol. 21, p. 1539

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-4-甲基苯甲腈 在 Rhodococcus rhodochrous ATCC BAA 870 cobalt nitrile hydratase 作用下， 以 aq. buffer 为溶剂， 生成 2-氨基-4-甲基苯甲酰胺
  参考文献：
  名称：

  来自玫瑰色红球菌 ATCC BAA 870 的钴腈水合酶的底物分析

  摘要：

  对来自玫瑰色红球菌 ATCC BAA 870 的钴腈水合酶的芳香底物特征进行了评估，并针对多种含腈化合物 (>60)。为了确定这种酶的底物限度，评估了大小从小 (90 Da) 到大 (325 Da) 的化合物。较大的化合物包括通过 Suzuki 偶联反应制备的具有双芳基轴的化合物、Morita-Baylis-Hillman 加合物、通过 Buchwald-Hartwig 交叉偶联反应制备的杂原子连接的二芳基吡啶和通过制备的咪唑并 [1,2-a] 吡啶Groebke-Blackburn-Bienaymé 多组分反应。酶活性位点适中，接受几乎所有的小芳香腈，二芳基吡啶和大多数双芳基化合物和 Morita-Baylis-Hillman 产品，但不是 Groebke-Blackburn-Bienaymé 产品。腈的转化率受氰基周围的空间位阻、芳环上给电子基团（例如甲氧基）的存在以及化合物的整体大小的影响。

  DOI：

  10.3390/molecules25010238
• 作为试剂：
  描述：

  4-甲基-2-硝基苯甲酰胺 、 氯化铵 在 铁粉 2-氨基-4-甲基苯甲酰胺 作用下， 以 乙醇 、 水 为溶剂， 以to afford 1.2 g of the title product的产率得到2-氨基-4-甲基苯甲酰胺
  参考文献：
  名称：

  Bicyclic compounds as mPGES-1 inhibitors

  摘要：

  本公开涉及式（I）化合物及其药学上可接受的盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗多种疾病或病况引起的疼痛和/或炎症方面非常有用，例如哮喘，骨关节炎，类风湿性关节炎，急性或慢性疼痛和神经退行性疾病。

  公开号：

  US09006257B2

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Iron nitrate/TEMPO-catalyzed aerobic oxidative synthesis of quinazolinones from alcohols and 2-aminobenzamides with air as the oxidant
  作者：Yongke Hu、Lei Chen、Bindong Li

  DOI：10.1039/c6ra12164k

  日期：——

  A highly efficient, Iron nitrate/TEMPO-catalyzed approach for the synthesis of quinazolinones has been achieved via a one-pot, tandem aerobic oxidative cyclization of primary alcohols with 2-aminobenzamides. This practical reaction tolerates...

  高效，硝酸铁/ TEMPO催化合成喹唑啉酮的方法是通过伯醇与2-氨基苯甲酰胺的一锅串联串联好氧氧化环化反应而实现的。这种实际反应可以容忍...
• Electrochemical oxidative synthesis of 2-benzoylquinazolin-4(3<i>H</i>)-one <i>via</i> C(sp³)–H amination under metal-free conditions
  作者：Yongzhi Hu、Xinhua Ma、Huiqing Hou、Weiming Sun、Shuqing Tu、Mei Wu、Rongkun Lin、Xiuzhi Xu、Fang Ke

  DOI：10.1039/d1cy01230d

  日期：——

  induced C(sp3)–H amination of 2-aminobenzamides with ketones using TBAI as a catalyst was developed, and provided 2-benzoylquinazolin-4(3H)-ones under metal-free conditions. The reaction proceeded using the relatively low-toxicity methanol as the solvent, employed molecular oxygen as the ideal green oxidant in a simple undivided cell, and exhibited high atom economy. The mechanism of this C(sp3)–H amination

  开发了使用 TBAI 作为催化剂的 2-氨基苯甲酰胺与酮的电化学诱导 C(sp 3 )-H 胺化，并在无金属条件下提供了 2-苯甲酰基喹唑啉-4(3 H )-酮。该反应以毒性相对较低的甲醇为溶剂，采用分子氧作为理想的绿色氧化剂，在一个简单的未分体电池中进行，表现出较高的原子经济性。这种 C(sp 3 )-H 胺化策略的机制被认为涉及苯乙酮自由基的产生，并且它很容易进一步氧化形成 2-oxo-2-苯基乙醛。
• Visible light induced tandem reactions: An efficient one pot strategy for constructing quinazolinones using in-situ formed aldehydes under photocatalyst-free and room-temperature conditions
  作者：Zongbo Xie、Jin Lan、Haibo Zhu、Gaoyi Lei、Guofang Jiang、Zhanggao Le

  DOI：10.1016/j.cclet.2020.09.059

  日期：2021.4

  aminobenzamides and in-situ generated aldehydes. Visible light was found to play a dual role: first oxidizes the alcohol to the aldehyde and then facilitates its cyclization with o-substituted aniline. Furthermore, alcohols are perfect alternatives to aldehydes because they are greener, more available, more economical, more stable, and less toxic than aldehydes. The first reaction step continuously

  已经开发了一种从各种氨基苯甲酰胺和原位生成的醛构建喹唑啉酮的简便串联途径。发现可见光起着双重作用：首先将醇氧化成醛，然后促进其与邻苯二甲酸的环化。取代的苯胺。此外，醇是醛的完美替代品，因为它们比醛更绿色，更易得，更经济，更稳定且毒性更低。第一反应步骤连续地为第二步骤提供材料，该材料有效地减少了由于醛的挥发，氧化和聚合而造成的损失，同时避免了其毒性。可以在可见光存在下制备各种喹唑啉酮，而无需任何其他光催化剂。发达的合成方案具有温和条件，广泛的底物范围，操作简便和高原子效率的优点，并在无金属，无光催化剂和环境条件下具有生态能源。
• QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Hadd Michael J.

  公开号：US20120053174A1

  公开（公告）日：2012-03-01

  Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了喹唑啉化合物，用于治疗JAK激酶介导的疾病，包括JAK2激酶、JAK3激酶或TYK2激酶介导的疾病。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。